Business & FinanceTop StoryTop StoryLatest News
Morepen Launches First US Prescription Generic, Eyes Further Filings
Sentiment: NeutralHigh Priority
What Happened?
Morepen Laboratories has launched its first prescription generic, Desloratadine Tablets USP, in the US market. The company aims to expand its presence in the prescription generics segment.
Key points
- Morepen's Desloratadine Tablets are available in 100-count and 500-count packs.
- The company has supplied Desloratadine API to the US market for several years.
- Morepen has submitted its first ANDA for Sitagliptin Phosphate Tablets, currently under FDA review.
- The company plans to pursue additional US prescription generic filings.
- Morepen may explore opportunities in high-potency APIs and oncology.
Key insights
- The launch could enhance Morepen's competitive position in the US pharmaceutical market.
- Expanding into finished-dosage medicines may lead to increased revenue streams for Morepen.
- The company's ongoing API relationships may support its growth strategy in regulated markets.
Why it matters
This launch marks Morepen's entry into the US prescription generics market, potentially expanding its business opportunities.
Tags
Entities
Morepen Laboratories· CompanyDesloratadine· ProductSitagliptin Phosphate· ProductUS· CountryFDA· Organization
Source
Business Standard
